DaVita Inc. stock advances as Q2 2026 earnings and guidance underpin strong valuation

Published on 09/10/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita Inc. stock closed at USD 183.54 on its primary US exchange on September 9, 2026, up 1.9 percent from the prior session and 61.81 percent year to date. Q2 2026 revenue rose 5.2 percent to USD 3.554 billion, with EPS jumping to USD 4.02.

Modernes Dialysezentrum mit Pflegepersonal und Patienten in heller Klinikumgebung — DaVita Inc. Dialysezentrum mit modernen Behandlungsstühlen und medizinischem Pflegepersonal in Denver, ISIN US23918K1088, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23918K1088) last closed at USD 183.54 on its primary US exchange on September 9, 2026, marking a 1.9 percent gain from the previous close and extending a year-to-date performance of 61.81 percent that clearly outpaces the broader health-care space, according to price data compiled from MarketScreener and relayed in recent market summaries. As of September 9, 2026, this level places DaVita firmly in the upper end of its recent trading band around USD 180 to 184, giving investors a valuation reference ahead of upcoming events.

Q2 2026 figures and guidance support the rally

Fundamentally, DaVita’s current valuation is anchored in its second-quarter 2026 results and reaffirmed guidance. According to DaVita in its release dated August 4, 2026, for the quarter ended June 30, 2026, consolidated revenue reached USD 3.554 billion, representing a 5.2 percent increase compared with the same period a year earlier. In the same quarter, operating income came in at USD 579 million, corresponding to an operating margin of 16.3 percent and illustrating that profitability has improved alongside revenue growth over this recent period.

The earnings power has also stepped up clearly. As StockTitan summarizes based on the same Q2 2026 report, diluted earnings per share for DaVita reached USD 4.02 in the quarter ended June 30, 2026, compared with USD 2.95 in the prior-year quarter, implying year-over-year EPS growth of roughly 36 percent. The portal also highlights that quarterly revenue rose 5.2 percent over the year-ago period, underscoring that DaVita is currently delivering both top-line and bottom-line expansion within the accepted freshness window for reported figures.

Guidance adds another layer of support for the stock’s current level. According to MarketBeat, DaVita reaffirmed its full-year 2026 guidance at the time of the Q2 release, including a midpoint of USD 2.2 billion for adjusted operating income and a midpoint of USD 14.65 for adjusted earnings per share. For investors, these figures suggest that the strong second quarter is not an isolated event but part of a broader trajectory that management still sees as achievable for 2026 as a whole.

Analyst expectations and valuation backdrop

Analyst consensus provides additional context for the current share price. According to Zacks in an article dated September 9, 2026, DaVita stock has rallied 58.5 percent year to date, compared with 22 percent growth for its industry and 11.6 percent for the S&P 500, confirming that the shares have significantly outperformed both their sector and a key equity benchmark. Zacks also reports that the consensus estimate for DaVita’s third-quarter 2026 revenue stands at USD 3.53 billion, indicating a projected 3.2 percent increase versus the prior-year quarter, while the consensus for earnings is USD 3.78 per share, implying 50.6 percent year-over-year growth.

Looking at broader analyst ratings, data compiled by MarketBeat show that four research analysts currently rate DaVita as a Buy and three as a Hold, resulting in an average rating of Moderate Buy. The same data set cites an average analyst price target of USD 233.43, which stands notably above the latest closing price of USD 183.54 as of September 9, 2026, suggesting that the sell-side still sees upside from current levels, even after the stock’s strong run so far in 2026.

Shorter-term sentiment indicators also point to a constructive stance, even if they reflect a different subset of the analyst community. Per the overview on Robinhood, 50 percent of the ten tracked analyst ratings on DaVita at present are classified as Buy, 40 percent as Hold and 10 percent as Sell, illustrating that while there is some caution in the coverage universe, positive recommendations still make up half of the sample.

Share price level and upcoming earnings date

In terms of trading characteristics, DaVita stock’s latest closing price of USD 183.54 on September 9, 2026 on its primary US exchange came after a previous close of USD 180.11, translating into the 1.9 percent daily advance reported in recent corporate news wraps derived from MarketScreener data. Those same wraps highlight that the stock has recently traded between USD 180 and USD 184 on several consecutive sessions, which for investors effectively marks a short-term consolidation band following the post-earnings volatility earlier in August 2026.

Market-derived data also point to a notable year-to-date climb. As compiled in recent DaVita coverage based on MarketScreener figures, the stock’s performance of 61.81 percent as of September 9, 2026 contrasts sharply with the S&P 500’s 11.6 percent gain over a similar period, underscoring that DaVita has turned into one of the stronger performers within its health-care niche in 2026. For valuation-oriented investors, the combination of a closing price near USD 183.50, double-digit revenue growth, sharply higher earnings per share and a supportive guidance range frames the current share level as being underpinned by measurable operating progress rather than purely by sentiment.

Looking ahead, the next key date for fundamentals is the upcoming third-quarter 2026 earnings release. According to the earnings calendar compiled by MarketBeat, DaVita’s Q3 2026 earnings are estimated to be reported on October 28, 2026, with a conference call scheduled for 5:00 p.m. Eastern Time on that date. For shareholders, this event will offer the next checkpoint to see whether the company can deliver the consensus revenue of USD 3.53 billion and earnings of USD 3.78 per share that Zacks currently projects, and whether the full-year 2026 guidance for adjusted operating income and EPS will be confirmed, raised or revised.